1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company

 
• By Jessica Merrill

Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.

Alexion Pharmaceuticals Inc. has had an impressive eight-year run with Soliris (eculizumab), building its one and only drug into a blockbuster by doggedly identifying new patients around the world with its two rare disease indications and securing reimbursement despite the drug’s exorbitant price – largely because of the breakthrough nature of the product and the ultra-small patient populations it targets.

Investors, pleased with Alexion's’ track record, have nonetheless been anxious to see the rare disease specialist diversify beyond a single product, especially as Soliris continues to penetrate

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.